文丨《星岛》记者 黄冬艳 广州报道近日的信达生物(01801.HK),可谓春风得意马蹄疾。继2月4日披露2025年业绩预告,宣布产品收入首次破百亿并达到119亿后,信达生物于2月8日又宣布了与老朋友礼来的一项最高总额可达88.5亿美元的重磅战略合作。消息一出,行业议论纷纷,且关注重点在于,支持上述合作3.5亿美元首付款的,并非成熟的临床在研管线,而更多是不确定更大的临床前分子。信达生物首席商务官张...
Source Link文丨《星岛》记者 黄冬艳 广州报道近日的信达生物(01801.HK),可谓春风得意马蹄疾。继2月4日披露2025年业绩预告,宣布产品收入首次破百亿并达到119亿后,信达生物于2月8日又宣布了与老朋友礼来的一项最高总额可达88.5亿美元的重磅战略合作。消息一出,行业议论纷纷,且关注重点在于,支持上述合作3.5亿美元首付款的,并非成熟的临床在研管线,而更多是不确定更大的临床前分子。信达生物首席商务官张...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.